IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
October 23, 2023 08:30 ET
|
Imunon, Inc.
Highlights advantages of IMUNON’s PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference
May 30, 2023 08:00 ET
|
Imunon, Inc.
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
December 01, 2022 16:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice...
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
October 15, 2021 09:00 ET
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference
September 30, 2019 14:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief...